Loading clinical trials...

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)

NCT05476926•Hoffmann-La Roche

Summary

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\. Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.

Exclusion Criteria

•1\. Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)

Locations (299)

Retinal Research Institute, LLC

Phoenix, Arizona, United States

California Eye Specialists Medical group Inc.

Pasadena, California, United States

Retinal Consultants Medical Group

Sacramento, California, United States

Advanced Research

Coral Springs, Florida, United States

Retina Specialty Institute

Pensacola, Florida, United States

University Retina and Macula Associates, PC

Lemont, Illinois, United States

Springfield Clinic, Llp

Springfield, Illinois, United States

Retina Associates of Kentucky

Lexington, Kentucky, United States

Cumberland Valley Retina Consultants PC

Hagerstown, Maryland, United States

Associated Retinal Consultants PC

Royal Oak, Michigan, United States

Key Dates

Start Date

November 21, 2022

Primary Completion Date

November 30, 2026

Completion Date

November 30, 2027

Last Updated

March 16, 2026

Enrollment

6,000

ESTIMATED participants

Conditions

Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein OcclusionBranch Retinal Vein OcclusionCentral Retinal Vein OcclusionHemi-retinal Vein Occlusion

Interventions

Faricimab

DRUG

Port Delivery System with Ranibizumab

COMBINATION_PRODUCT

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936

Diabetic Macular EdemaDME+1 more

View study

RECRUITINGPHASE3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449923

Diabetic Macular EdemaDME+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Inclusion Criteria

Exclusion Criteria

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

A Study of Avoralstat In Participants With Diabetic Macular Edema

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)